A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Inhaled QBW276 in Patients With Cystic Fibrosis
Phase of Trial: Phase I/II
Latest Information Update: 17 Nov 2017
At a glance
- Drugs QBW 276 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Novartis
- 09 Nov 2017 Planned End Date changed from 11 Jul 2019 to 11 Sep 2019.
- 09 Nov 2017 Planned primary completion date changed from 11 Jul 2019 to 11 Sep 2019.
- 09 Nov 2017 Status changed from not yet recruiting to recruiting.